Date:5/6/2009

it is patient friendly for those with heart failure," says Dr. Kocheril. Shape-HF™ uses low intensity, sub-maximal or steady state testing protocols to allow testing of even high-risk patients with little or no discomfort.
   
Cardiologists know that measuring patient gas exchange is the best method of assessing patient functional capacity, monitoring their response to therapy and predicting outcome. Shape-HF™ is designed to quantify the severity of dyspnea on exertion and fatigue and evaluate the interaction between the heart, lungs, and other organ systems. This makes it possible for the physician to evaluate therapy options for the individual patient and track patient progress. In addition, cardiac resynchronization therapy (CRT) has become a mainstay in treating patients with severe heart failure when alternative treatment options have been exhausted. According to Dr. Koucheril, "The CRT response rate in heart failure patients is about 70%. The Shape-HF™ System is likely to help us get the remaining 30% feeling better--those we call non-responders--because it lets us objectively measure response to CRT and optimize timing between the atrium and the two ventricles of the heart in real time while the patient is exercising."
   
In addition to being the first and only device that objectively measures cardiopulmonary gas exchange easily and quickly without undue strain on the patient and in the office setting, Shape-HF™ provides real-time physiological assessment to enable CRT optimization during exercise and is cost-effective and easy to use. According to Shape Medical Systems President and COO Clarence Johnson, "Cost, logistics and the complexity of testing and data interpretation, as well as the significant level of patient discomfort associated with cardiopulmonary exercise testing has limited its utility and deprived physicians and their patients of much needed physiologi
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. University of Leicester scientists discover technique to help friendly bacteria
7. MichBio Announces Student Career Day at Michigan State University
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
11. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples